Structure-based design of potent CDK1 inhibitors derived from olomoucine

被引：36

作者：

Furet, P ^{[1
]}

Zimmermann, J ^{[1
]}

Capraro, HG ^{[1
]}

Meyer, T ^{[1
]}

Imbach, P ^{[1
]}

机构：

[1] Novartis, Oncol Res Dept, CH-4002 Basel, Switzerland

来源：

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN | 2000年 / 14卷 / 05期

关键词：

cyclin-dependent kinase; CDK1; inhibitor; olomoucine; structure-based design;

D O I：

10.1023/A:1008115004986

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, constitutes a possible target in the search for new antitumor agents. Starting from the purine derivative olomoucine and following a structure-based approach, potent inhibitors of this enzyme were rapidly identified. The molecular modeling aspects of this work are described.

引用

页码：403 / 409

页数：7

共 28 条

[1] Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors [J].

Chang, YT ;

Gray, NS ;

Rosania, GR ;

Sutherlin, DP ;

Kwon, S ;

Norman, TC ;

Sarohia, R ;

Leost, M ;

Meijer, L ;

Schultz, PG .

CHEMISTRY & BIOLOGY, 1999, 6 (06) :361-375

[2] Chemical inhibitors of cyclin-dependent kinases [J].

Coleman, KG ;

Lyssikatos, JP ;

Yang, BV .

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 32, 1997, 32 :171-179

[3] Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine [J].

DeAzevedo, WF ;

Leclerc, S ;

Meijer, L ;

Havlicek, L ;

Strnad, M ;

Kim, SH .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2) :518-526

[4] Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase [J].

deAzevedo, WF ;

MuellerDieckmann, HJ ;

SchulzeGahmen, U ;

Worland, PJ ;

Sausville, E ;

Kim, SH .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) :2735-2740

[5] CRYSTAL-STRUCTURE OF CYCLIN-DEPENDENT KINASE-2 [J].

DEBONDT, HL ;

ROSENBLATT, J ;

JANCARIK, J ;

JONES, HD ;

MORGAN, DO ;

KIM, SH .

NATURE, 1993, 363 (6430) :595-602

[6]

DODIN G, 1979, J CHEM SOC P2, V4, P438

[7]

HANKS SK, 1991, METHOD ENZYMOL, V200, P38

[8] Cytokinin-derived cyclin-dependent kinase inhibitors: Synthesis and cdc2 inhibitory activity of olomoucine and related compounds [J].

Havlicek, L ;

Hanus, J ;

Vesely, J ;

Leclerc, S ;

Meijer, L ;

Shaw, G ;

Strnad, M .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (04) :408-412

[9] Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases [J].

Hoessel, R ;

Leclerc, S ;

Endicott, JA ;

Nobel, MEM ;

Lawrie, A ;

Tunnah, P ;

Leost, M ;

Damiens, E ;

Marie, D ;

Marko, D ;

Niederberger, E ;

Tang, WC ;

Eisenbrand, G ;

Meijer, L .

NATURE CELL BIOLOGY, 1999, 1 (01) :60-67

[10] 2,6,9-trisubstituted purines: Optimization towards highly potent and selective CDK1 inhibitors [J].

Imbach, P ;

Capraro, HG ;

Furet, P ;

Mett, H ;

Meyer, T ;

Zimmermann, J .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (01) :91-96

← 1 2 3 →